Printer Friendly

NEW ONCE-A-DAY DRUG FOR ANGINA GAINS U.S. MARKET CLEARANCE

    MADISON, N.J., Aug. 13 /PRNewswire/ -- The first oral, once-a-day nitrate compound for the prevention of angina due to coronary artery disease has received government marketing clearance, Schering-Plough Corporation (NYSE: SGP) announced today.  The product will be marketed under the brand name IMDUR (isosorbide mononitrate) extended release tablets.
    "When used according to its convenient once-a-day dosing schedule, IMDUR has been shown to maintain its efficacy," noted Jonathan Spicehandler, M.D., president of Schering-Plough Research Institute. "We are pleased to be able to offer this important therapeutic advance to physicians and patients."
    Stephen P. Glasser, M.D., professor of medicine and director of clinical pharmacology, University of South Florida College of Medicine, conducted several clinical trials with IMDUR.  "This drug's formulation provides sustained benefit over 12 hours with once-a-day dosing.  This makes it a very important addition to the drugs currently available for treatment of angina."
    Side effects seen with IMDUR in clinical trials were similar to those reported with other nitrates.  The most common were headache (which is treatable with aspirin), dizziness and nausea.
    IMDUR, to be available in October by prescription only in pharmacies nationwide, will be priced competitively with existing long-acting nitrate formulations.
    "Marketing clearance of IMDUR marks a significant achievement for Schering-Plough," said Richard J. Kogan, president and chief operating officer.  "We already have a strong position in the nitroglycerin patch market, and this clearance gives us a unique entry into the oral nitrate market."  The NITRO-DUR (nitroglycerin) transdermal infusion system is the No. 1 prescribed product in its category in the United States, and K-DUR 20 (potassium chloride, USP) Microburst Release System potassium supplement tablets is the No. 1 prescribed product in its category domestically as well.
    Through targeted research and strategic licensing agreements, including the 1986 acquisition of Key Pharmaceuticals, Schering-Plough has developed a strong cardiovascular products line.  In addition to the NITRO-DUR transdermal infusion system and K-DUR 20 potassium supplements, the company's stable of products includes K-DUR 10 (potassium chloride, USP) potassium supplements and NORMODYNE (labetalol hydrochloride) antihypertensive tablets and injection. IMDUR is licensed from ASTRA HASSLE, AB, Sweden.
    Schering-Plough Corporation is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide.  The company manufactures and markets prescription pharmaceuticals through its Schering-Plough Pharmaceuticals operating unit, which includes Schering Laboratories and Key Pharmaceuticals labels.
    -0-             08/13/93
    CONTACT:  Ronald J. Asinari, 201-822-7402, or Karen Reine, 212-684-6300, both of Schering-Plough Corporation
    (SGP) CO:  SCHERING-PLOUGH CORPORATION IN:  MTC SU:  PDT ST:  NJ


-- NY013 -- X526 08/13/93
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 13, 1993
Words:419
Previous Article:FIELDCREST CANNON, AMOSKEAG ANNOUNCE AGREEMENT
Next Article:TELEPAD APPOINTS JOSEPH J. ELKINS AS VICE PRESIDENT OF FINANCE AND ADMINISTRATION
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters